Flerie AB (FLERIE) Fair Value & Analysis
Healthcare · SE · Market cap 2.1B SEK
Fair value as of: Jul 16, 2026
From 1 valuation models · updated today
Share price −7.0% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 19.90 – kr 41.26 · fair‑value band kr 4.17 – kr 7.90 · the kr 20.00 price screens above the kr 6.32 fair value. As of Jul 16, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Flerie AB (FLERIE) currently trades at kr 20.00, while our model-based Fair Value estimate is kr 6.32 — implying the stock looks roughly 68.4% overvalued today. We read business quality at 22/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 1.8M SEK. Revenue declined 87.5% year over year. It earns a return on equity of -14.9%. The balance sheet holds a net cash position of 537M SEK. Fundamentals as of Jul 16, 2026
Our scenario range runs from kr 4.17 (bear case) to kr 7.90 (bull case); at kr 20.00, the current price sits above that range. The share trades about 52% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -23% fair-value upside — at -68%, FLERIE screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 16, 2026. TTM = trailing twelve months.
About the company
Flerie AB (publ) is a venture capital firm specializing in early-stage investments. The firm seeks to invest in life science, biotech and pharma companies engaged in drug development and associated tools or applications tackling major medical challenges of our time. The firm seeks to invest in Europe, Nordic, United States and Israel. Flerie AB (publ) was founded in 2011 and is based in Stockholm, Sweden with additional office in London, United Kingdom.
Revenue & earnings trend
FY2020 – FY2025 · reported fiscal years
Flerie AB reported revenue of kr 8.8M in FY2025 versus kr 35.0K in FY2020, a compound +202.1%/yr. Reported net income was −kr 757M in FY2025.
Is FLERIE fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
| CSL Limited CSL | A$97.91 | A$100.60 | +3% |
| Celltrion, Inc 068270 | 167,300 KRW | 76,382 KRW | -54% |
| BioNTech SE B1NT34 | R$29.19 | R$21.38 | -27% |
| WuXi Biologics (Cayman) Inc 2269 | HK$30.74 | HK$28.99 | -6% |
| Moderna, Inc M1RN34 | R$12.44 | R$5.11 | -59% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Flerie AB (FLERIE) undervalued?
What is the fair value of FLERIE?
What is the quality score of FLERIE?
What is the revenue of Flerie AB (FLERIE)?
What is the net profit margin of FLERIE?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Tell me when Flerie AB reaches its Fair Value
Just your email — and we'll notify you when the price and Fair Value of Flerie AB materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.